- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04163081
Die INITIATE-Studie: Beginn der Nikotinabhängigkeitsbehandlung für Raucher, die in Notaufnahmen aufgenommen wurden (INITIATE)
The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Evyanne Wooding, R.Kin
- Telefonnummer: 17596 613-696-7000
- E-Mail: ewooding@ottawaheart.ca
Studieren Sie die Kontaktsicherung
- Name: Chantelle Masterson, BPhil
- Telefonnummer: 19157 613-696-7000
- E-Mail: cmasterson@ottawaheart.ca
Studienorte
-
-
Ontario
-
Ottawa, Ontario, Kanada
- Rekrutierung
- University of Ottawa Heart Institute
-
Kontakt:
- Dr. Kerri-Anne Mullen
- Telefonnummer: 613-696-7000 ext.19095
- E-Mail: KMullen@ottawaheart.ca
-
Ottawa, Ontario, Kanada
- Rekrutierung
- Civic Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Telefonnummer: 6137985555,17023
- E-Mail: vthirug@toh.ca
-
Ottawa, Ontario, Kanada
- Rekrutierung
- General Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Telefonnummer: 6137985555,17023
- E-Mail: vthirug@toh.ca
-
Ottawa, Ontario, Kanada
- Rekrutierung
- Riverside Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Telefonnummer: 6137985555,17023
- E-Mail: vthirug@toh.ca
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Current daily smoker (smokes ≥ 5 cigarettes per day);
- ≥ 18 years of age (the age of majority in Ontario);
- For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
- Able to read and understand English or French;
- Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
- Available and willing to participate in follow-up assessments over the next 12 months;
- Has access to a telephone or computer;
- Able to provide informed consent
Exclusion Criteria:
- Currently participating in this or another smoking cessation study;
- For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
- Pregnant, planning to become pregnant over the next year, or breastfeeding;
- Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
- In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
- Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Quit Card Intervention (QCI)
Study intervention group. |
The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist. |
|
Kein Eingriff: Usual Care (UC)
Study control group. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Smoking Abstinence
Zeitfenster: 26 weeks (6 months) after study enrollment
|
Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test |
26 weeks (6 months) after study enrollment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Prolonged Abstinence
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Point Prevalence Abstinence
Zeitfenster: 4, and 52 weeks after study enrollment
|
Point prevalence smoking abstinence, at 4, and 52 weeks |
4, and 52 weeks after study enrollment
|
|
Smoking Reduction
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Number of Quit Attempts
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of quit attempts since study entry, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cessation Medication and/or E-cigarette Use
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Use of Behavioural Supports
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health-Related Quality of Life
Zeitfenster: 52 weeks after study enrollment
|
Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
52 weeks after study enrollment
|
|
Health Services Outcomes - ED visits
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Hospital Admissions
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Deaths
Zeitfenster: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cost-Effectiveness Ratios
Zeitfenster: 52 weeks after study enrollment
|
Cost-effectiveness ratios related to health services at 52 weeks |
52 weeks after study enrollment
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Kerri-Anne Mullen, PhD, Ottawa Heart Institute Research Corporation
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20190485-01H
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .